Anko Bio announced that the UTAA09 injection jointly developed by Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. and Boshengji Anko Cell Technology Co., Ltd., in which the company holds a stake, has obtained implicit approval from the Center for Drug Evaluation of the National Medical Products Administration. The drug is the world's first generic off-the-shelf CD19-UCAR-Vδ1T cell product approved for clinical trials, and is indicated for adult relapsed/refractory acute B-lymphocytic leukemia (B-ALL).